Alkem Labs Posts Robust Q2 FY26 Performance: Revenue at ₹40 Billion, Net Profit Climbs to ₹7.65 Billion

Alkem Laboratories, a leading pharmaceutical company, announced its consolidated financial results for the quarter ended September 2025. The total revenue from operations stood at ₹40.01 billion, reflecting robust sales growth driven by strong demand in both the Indian and international markets.

The consolidated net profit for the quarter rose to ₹7.65 billion, marking an 11% year-over-year increase. This growth was underpinned by better operational efficiencies and margin expansion despite inflationary pressures. The company’s EBITDA improved substantially, with margins inching higher on the back of strategic cost management and higher revenue quality.

Key operational highlights include significant progress in the US and other global markets, supported by successful product launches and an efficient supply chain. Alkem Labs maintained a solid balance sheet with good cash flow generation and declared an interim dividend for shareholders.

Important Points:

- Consolidated revenue from operations reached ₹40.01 billion in Q2 FY26.
- Net profit increased by 11% year-on-year to ₹7.65 billion.
- EBITDA margin improved, reflecting better cost control and operational efficiencies.
- Strong sales growth across India and key international markets, including the US.
- Continued product launches and market expansion boosted performance.
- Interim dividend announced, indicating confidence in future cash flows.
- Resilient financial performance amid cost pressures and market challenges.

Sources: NSE Circular, Alkem Laboratories official disclosures, Moneycontrol, CNBC TV18, Hindustan Times.